Fuan Pharmaceutical (Group) Co., Ltd. (SHE:300194)
China · Delayed Price · Currency is CNY 3.890
+0.030 (0.78%)
Sep 30, 2026, 3:04 PM CST
SHE:300194 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,597 | 1,678 | 2,308 | 2,571 | 2,378 | 2,388 |
Other Revenue | 60.03 | 60.17 | 83.1 | 76.94 | 44.22 | 64.71 |
| 1,657 | 1,738 | 2,391 | 2,648 | 2,422 | 2,453 | |
Revenue Growth | -11.81% | -27.31% | -9.68% | 9.33% | -1.28% | 3.58% |
Cost of Revenue | 1,054 | 1,131 | 1,174 | 1,281 | 1,066 | 935.97 |
Gross Profit | 603.21 | 607.61 | 1,218 | 1,367 | 1,355 | 1,517 |
Selling, General & Admin | 381.81 | 400.6 | 804.89 | 1,021 | 1,092 | 1,217 |
Research & Development | 118.66 | 134.66 | 153.22 | 148.79 | 142.89 | 120.38 |
Other Operating Expenses | 18.1 | 9.38 | 6.9 | 15.31 | 16.28 | 28.08 |
Operating Expenses | 517.13 | 550.92 | 968.97 | 1,182 | 1,255 | 1,370 |
Operating Income | 86.08 | 56.69 | 248.55 | 184.51 | 100.24 | 147.59 |
Interest Expense | -18.46 | -22.15 | -23.34 | -29.57 | -26.94 | -20.45 |
Interest & Investment Income | 119.67 | 168.16 | 106.8 | 109.41 | 90.07 | 74.46 |
Currency Exchange Gain (Loss) | -1.28 | 0.2 | 0.98 | 0.66 | 1.47 | -0.59 |
Other Non Operating Income (Expenses) | -0.23 | -0.66 | -0.45 | -0.85 | -1.4 | -1.76 |
EBT Excluding Unusual Items | 185.78 | 202.23 | 332.54 | 264.17 | 163.44 | 199.26 |
Impairment of Goodwill | -129.02 | -129.02 | - | -224.51 | -22.97 | -201.06 |
Gain (Loss) on Sale of Investments | -1.96 | -1.86 | -32.74 | 0.41 | 0.42 | 0.75 |
Gain (Loss) on Sale of Assets | 0.31 | 0.27 | 0.01 | 220.65 | 4.85 | 0.31 |
Asset Writedown | -3.46 | -2.65 | -4.92 | -3.61 | -2.44 | -626.17 |
Other Unusual Items | 19.1 | 14.28 | 17.3 | 33.24 | 46.07 | 34.93 |
Pretax Income | 70.76 | 83.24 | 312.2 | 290.36 | 189.35 | -591.99 |
Income Tax Expense | 11.48 | 6.76 | 34.03 | 55.95 | -11.47 | 17.61 |
Earnings From Continuing Operations | 59.28 | 76.49 | 278.17 | 234.41 | 200.82 | -609.59 |
Minority Interest in Earnings | 0.37 | 0.51 | 1.67 | -2.54 | 3.79 | 312.68 |
Net Income | 59.65 | 77 | 279.84 | 231.87 | 204.61 | -296.91 |
Net Income to Common | 59.65 | 77 | 279.84 | 231.87 | 204.61 | -296.91 |
Net Income Growth | -66.20% | -72.48% | 20.69% | 13.32% | - | - |
Shares Outstanding (Basic) | 1,316 | 1,283 | 1,166 | 1,220 | 1,204 | 1,188 |
Shares Outstanding (Diluted) | 1,316 | 1,283 | 1,166 | 1,220 | 1,204 | 1,188 |
Shares Change | 16.46% | 10.06% | -4.46% | 1.40% | 1.34% | 2.10% |
EPS (Basic) | 0.05 | 0.06 | 0.24 | 0.19 | 0.17 | -0.25 |
EPS (Diluted) | 0.05 | 0.06 | 0.24 | 0.19 | 0.17 | -0.25 |
EPS Growth | -70.98% | -75.00% | 26.32% | 11.77% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 352.27 | 203.89 | 61.8 | 113.3 | -43.6 | -155.91 |
Free Cash Flow Per Share | 0.27 | 0.16 | 0.05 | 0.09 | -0.04 | -0.13 |
Dividend Per Share | 0.050 | 0.070 | 0.050 | 0.050 | 0.050 | - |
Dividend Growth | -28.57% | 40.00% | 0% | 0% | 0% | - |
Gross Margin | 36.40% | 34.96% | 50.91% | 51.63% | 55.97% | 61.85% |
Operating Margin | 5.20% | 3.26% | 10.39% | 6.97% | 4.14% | 6.02% |
Profit Margin | 3.60% | 4.43% | 11.70% | 8.76% | 8.45% | -12.10% |
Free Cash Flow Margin | 21.26% | 11.73% | 2.58% | 4.28% | -1.80% | -6.35% |
EBITDA | 287.11 | 260.54 | 446.01 | 392.88 | 284.11 | 321.89 |
EBITDA Margin | 17.33% | 14.99% | 18.65% | 14.84% | 11.73% | 13.12% |
D&A For EBITDA | 201.03 | 203.86 | 197.45 | 208.37 | 183.87 | 174.29 |
EBIT | 86.08 | 56.69 | 248.55 | 184.51 | 100.24 | 147.59 |
EBIT Margin | 5.20% | 3.26% | 10.39% | 6.97% | 4.14% | 6.02% |
Effective Tax Rate | 16.23% | 8.12% | 10.90% | 19.27% | - | - |
Revenue as Reported | 1,657 | 1,738 | 2,391 | 2,648 | 2,422 | 2,453 |
Advertising Expenses | - | 18.89 | 24.05 | 2.44 | 0.48 | 0.5 |